72873-74-6|SKF86002|6-(4-Fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]-thiazole|-范德生物科技公司

SKF86002

NMR下载 COA and HPLC MSDS下载
names：
6-(4-Fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]-thiazole
CAS号：
72873-74-6
MDL Number：
MF(分子式)： C16H12FN3S MW(分子量)： 297.3514
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	6-(4-Fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]-thiazole
英文别名	SKF-86002; SKF 86002; SKF86002.
CAS号	72873-74-6
SMILES	FC1=CC=C(C2=C(C3=CC=NC=C3)N4C(SCC4)=N2)C=C1
Inchi	InChI=1S/C16H12FN3S/c17-13-3-1-11(2-4-13)14-15(12-5-7-18-8-6-12)20-9-10-21-16(20)19-14/h1-8H,9-10H2
InchiKey	YOELZIQOLWZLQC-UHFFFAOYSA-N
分子式 Formula	C16H12FN3S
分子量 Molecular Weight	297.3514
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	SKF86002(CAS:72873-74-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	SKF86002 is a p38 MAP kinase inhibitor. SKF86002 inhibits IL-1 beta production by affecting at least two distinct steps in the biosynthesis of this cytokine.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Khattab M, Van Dongen M, Wang F, Clayton AH. Solvatochromism and linear solvation energy relationship of the kinase inhibitor SKF86002. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jan 5;170:226-33. doi: 10.1016/j.saa.2016.07.027. PubMed PMID: 27450120.

[2]Dai HL, Hu WY, Jiang LH, Li L, Gaung XF, Xiao ZC. p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive Mice. Sci Rep. 2016 Jun 10;

6:27600. doi: 10.1038/srep27600. PubMed PMID: 27283322; PubMed Central PMCID: PMC4901328.

[4]Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE; AIDS Malignancy Consortium (AMC)-059 Study Team.. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr. 2016 May 1;72(1):52-7. doi: 10.1097/QAI.0000000000000918. PubMed PMID: 26689971; PubMed Central PMCID: PMC4838493.

[5] Mizukoshi Y, Takeuchi K, Arutaki M, Takizawa T, Hanzawa H, Takahashi H, Shimada I. Suppression of problematic compound oligomerization by cosolubilization of nondetergent sulfobetaines. ChemMedChem. 2015 Apr;10(4):736-41. doi: 10.1002/cmdc.201500057. PubMed PMID: 25760302; PubMed Central PMCID: PMC4471626.

5: Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 2015 Jan;121(1):217-24. doi: 10.1007/s11060-014-1665-1. PubMed PMID: 25407389; PubMed Central PMCID: PMC4330963.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开